561 related articles for article (PubMed ID: 26384981)
1. Efficacy and safety of novel oral anticoagulants in patients with bioprosthetic valves.
Yadlapati A; Groh C; Malaisrie SC; Gajjar M; Kruse J; Meyers S; Passman R
Clin Res Cardiol; 2016 Mar; 105(3):268-72. PubMed ID: 26384981
[TBL] [Abstract][Full Text] [Related]
2. How to define valvular atrial fibrillation?
Fauchier L; Philippart R; Clementy N; Bourguignon T; Angoulvant D; Ivanes F; Babuty D; Bernard A
Arch Cardiovasc Dis; 2015 Oct; 108(10):530-9. PubMed ID: 26184867
[TBL] [Abstract][Full Text] [Related]
3. Stroke prevention strategies in patients with atrial fibrillation and heart valve abnormalities: perceptions of 'valvular' atrial fibrillation: results of the European Heart Rhythm Association Survey.
Potpara TS; Lip GY; Larsen TB; Madrid A; Dobreanu D; Jędrzejczyk-Patej E; Dagres N;
Europace; 2016 Oct; 18(10):1593-1598. PubMed ID: 27876696
[TBL] [Abstract][Full Text] [Related]
4. Edoxaban for the Prevention of Thromboembolism in Patients With Atrial Fibrillation and Bioprosthetic Valves.
Carnicelli AP; De Caterina R; Halperin JL; Renda G; Ruff CT; Trevisan M; Nordio F; Mercuri MF; Antman E; Giugliano RP;
Circulation; 2017 Mar; 135(13):1273-1275. PubMed ID: 28209729
[No Abstract] [Full Text] [Related]
5. Nonvitamin K Antagonist Oral Anticoagulants Use in Patients with Atrial Fibrillation and Bioprosthetic Heart Valves/Prior Surgical Valve Repair: A Multicenter Clinical Practice Experience.
Russo V; Attena E; Mazzone C; Esposito F; Parisi V; Bancone C; Rago A; Nigro G; Sangiuolo R; D' Onofrio A
Semin Thromb Hemost; 2018 Jun; 44(4):364-369. PubMed ID: 29304513
[TBL] [Abstract][Full Text] [Related]
6. Oral anticoagulants in atrial fibrillation with valvular heart disease and bioprosthetic heart valves.
Malik AH; Yandrapalli S; Aronow WS; Panza JA; Cooper HA
Heart; 2019 Sep; 105(18):1432-1436. PubMed ID: 31203254
[TBL] [Abstract][Full Text] [Related]
7. Is early antithrombotic therapy necessary in patients with bioprosthetic aortic valves in normal sinus rhythm?
ElBardissi AW; DiBardino DJ; Chen FY; Yamashita MH; Cohn LH
J Thorac Cardiovasc Surg; 2010 May; 139(5):1137-45. PubMed ID: 20303508
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of apixaban vs warfarin in patients with atrial fibrillation and prior bioprosthetic valve replacement or valve repair: Insights from the ARISTOTLE trial.
Guimarães PO; Pokorney SD; Lopes RD; Wojdyla DM; Gersh BJ; Giczewska A; Carnicelli A; Lewis BS; Hanna M; Wallentin L; Vinereanu D; Alexander JH; Granger CB
Clin Cardiol; 2019 May; 42(5):568-571. PubMed ID: 30907005
[TBL] [Abstract][Full Text] [Related]
9. Antithrombotic therapy in atrial fibrillation associated with valvular heart disease: a joint consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE).
Lip GYH; Collet JP; Caterina R; Fauchier L; Lane DA; Larsen TB; Marin F; Morais J; Narasimhan C; Olshansky B; Pierard L; Potpara T; Sarrafzadegan N; Sliwa K; Varela G; Vilahur G; Weiss T; Boriani G; Rocca B;
Europace; 2017 Nov; 19(11):1757-1758. PubMed ID: 29096024
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of percutaneous left atrial appendage closure to prevent thromboembolic events in atrial fibrillation patients with high stroke and bleeding risk.
Seeger J; Bothner C; Dahme T; Gonska B; Scharnbeck D; Markovic S; Rottbauer W; Wöhrle J
Clin Res Cardiol; 2016 Mar; 105(3):225-9. PubMed ID: 26318322
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of early parenteral anticoagulation as a bridge to warfarin after mechanical valve replacement.
Mathew JG; Spyropoulos AC; Yusuf A; Vincent J; Eikelboom J; Shestakovska O; Fremes S; Noora J; Guo L; Peterson M; Pai M; Whitlock R
Thromb Haemost; 2014 Dec; 112(6):1120-8. PubMed ID: 25183209
[TBL] [Abstract][Full Text] [Related]
12. Risk factors for thromboembolic and bleeding events in anticoagulated patients with atrial fibrillation: the prospective, multicentre observational PREvention oF thromboembolic events - European Registry in Atrial Fibrillation (PREFER in AF).
Rohla M; Weiss TW; Pecen L; Patti G; Siller-Matula JM; Schnabel RB; Schilling R; Kotecha D; Lucerna M; Huber K; De Caterina R; Kirchhof P
BMJ Open; 2019 Mar; 9(3):e022478. PubMed ID: 30928922
[TBL] [Abstract][Full Text] [Related]
13. Safety and Use of Anticoagulation After Aortic Valve Replacement With Bioprostheses: A Meta-Analysis.
Riaz H; Alansari SA; Khan MS; Riaz T; Raza S; Luni FK; Khan AR; Riaz IB; Krasuski RA
Circ Cardiovasc Qual Outcomes; 2016 May; 9(3):294-302. PubMed ID: 27166205
[TBL] [Abstract][Full Text] [Related]
14. Clinical Benefit of Direct Oral Anticoagulants Versus Vitamin K Antagonists in Patients with Atrial Fibrillation and Bioprosthetic Heart Valves.
Russo V; Carbone A; Attena E; Rago A; Mazzone C; Proietti R; Parisi V; Scotti A; Nigro G; Golino P; D'Onofrio A
Clin Ther; 2019 Dec; 41(12):2549-2557. PubMed ID: 31735436
[TBL] [Abstract][Full Text] [Related]
15. Thromboembolic Risk, Bleeding Outcomes and Effect of Different Antithrombotic Strategies in Very Elderly Patients With Atrial Fibrillation: A Sub-Analysis From the PREFER in AF (
Patti G; Lucerna M; Pecen L; Siller-Matula JM; Cavallari I; Kirchhof P; De Caterina R
J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28736385
[TBL] [Abstract][Full Text] [Related]
16. Oral anticoagulation, stroke and thromboembolism in patients with atrial fibrillation and valve bioprosthesis. The Loire Valley Atrial Fibrillation Project.
Philippart R; Brunet-Bernard A; Clementy N; Bourguignon T; Mirza A; Angoulvant D; Babuty D; Lip GY; Fauchier L
Thromb Haemost; 2016 May; 115(5):1056-63. PubMed ID: 26843425
[TBL] [Abstract][Full Text] [Related]
17. Rationale, Design, and Baseline Characteristics of the BioProsthetic Valves with Atrial Fibrillation (BPV-AF) Study.
Furukawa Y; Miyake M; Fujita T; Koyama T; Takegami M; Kimura T; Sugio K; Takita A; Nishimura K; Izumi C;
Cardiovasc Drugs Ther; 2020 Oct; 34(5):689-696. PubMed ID: 32710129
[TBL] [Abstract][Full Text] [Related]
18. Non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients undergoing elective cardioversion.
Itäinen S; Lehto M; Vasankari T; Mustonen P; Kotamäki M; Numminen A; Lahtela H; Bah A; Hartikainen J; Hekkala AM; Airaksinen JKE
Europace; 2018 Apr; 20(4):565-568. PubMed ID: 29016758
[TBL] [Abstract][Full Text] [Related]
19. Aniticoagulation in patients following prosthetic heart valve replacement.
Akhtar RP; Abid AR; Zafar H; Khan JS
Ann Thorac Cardiovasc Surg; 2009 Feb; 15(1):10-7. PubMed ID: 19262444
[TBL] [Abstract][Full Text] [Related]
20. Direct Oral Anticoagulation Versus Warfarin in Patients with Atrial Fibrillation and Bioprosthetic Heart Valves: a Retrospective, Real-World Cohort Study.
Eikelboom R; Whitlock RP; Sibilio S; Nguyen F; Perez R; Weitz JI; Belley-Cote E
Cardiovasc Drugs Ther; 2024 Feb; 38(1):109-117. PubMed ID: 36121587
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
